Last reviewed · How we verify
L19TNF and TMZ in recurrent astrocytoma
L19TNF and TMZ in recurrent astrocytoma is a Biologic drug developed by Philogen S.p.A.. It is currently in Phase 2 development.
At a glance
| Generic name | L19TNF and TMZ in recurrent astrocytoma |
|---|---|
| Sponsor | Philogen S.p.A. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19TNF and TMZ in recurrent astrocytoma CI brief — competitive landscape report
- L19TNF and TMZ in recurrent astrocytoma updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI
Frequently asked questions about L19TNF and TMZ in recurrent astrocytoma
What is L19TNF and TMZ in recurrent astrocytoma?
L19TNF and TMZ in recurrent astrocytoma is a Biologic drug developed by Philogen S.p.A..
Who makes L19TNF and TMZ in recurrent astrocytoma?
L19TNF and TMZ in recurrent astrocytoma is developed by Philogen S.p.A. (see full Philogen S.p.A. pipeline at /company/philogen-s-p-a).
What development phase is L19TNF and TMZ in recurrent astrocytoma in?
L19TNF and TMZ in recurrent astrocytoma is in Phase 2.